Were Analysts Bearish Emergent BioSolutions Inc. (NYSE:EBS) This Week?

June 14, 2018 - By Adrian Erickson

Emergent BioSolutions Inc. (NYSE:EBS) LogoInvestors sentiment decreased to 1.77 in Q1 2018. Its down 0.25, from 2.02 in 2017Q4. It turned negative, as 10 investors sold Emergent BioSolutions Inc. shares while 65 reduced holdings. 56 funds opened positions while 77 raised stakes. 38.34 million shares or 3.95% more from 36.89 million shares in 2017Q4 were reported.
Chicago Equity Limited Liability holds 0.19% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 115,560 shares. Royal Bank Of Canada owns 0.03% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 1.17M shares. Gotham Asset Mngmt Llc stated it has 0.02% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Renaissance Tech Limited Liability Corporation has invested 0.11% in Emergent BioSolutions Inc. (NYSE:EBS). Parkside Fin Retail Bank And holds 0% in Emergent BioSolutions Inc. (NYSE:EBS) or 23 shares. Employees Retirement Association Of Colorado invested in 0% or 7,126 shares. 36,752 were reported by Ny State Teachers Retirement. James Inv Rech, a Ohio-based fund reported 44,263 shares. Assetmark invested in 0% or 175 shares. Credit Agricole S A holds 36,000 shares or 0.13% of its portfolio. Gemmer Asset Ltd Company accumulated 90 shares. Qs Investors Limited Company has 101,504 shares for 0.05% of their portfolio. Etrade Cap Mngmt Ltd Limited Liability Company reported 27,299 shares stake. Clark Capital invested 0.08% in Emergent BioSolutions Inc. (NYSE:EBS). Wellington Mgmt Gp Llp reported 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS).

Since January 2, 2018, it had 0 buys, and 11 insider sales for $4.28 million activity. Another trade for 1,377 shares valued at $70,434 was made by Zoon Kathryn C on Thursday, May 24. Richard Ronald also sold $434,115 worth of Emergent BioSolutions Inc. (NYSE:EBS) shares. Abdun-Nabi Daniel also sold $1.05 million worth of Emergent BioSolutions Inc. (NYSE:EBS) on Tuesday, January 2. Another trade for 5,842 shares valued at $308,574 was made by Havey Adam on Friday, March 9. On Monday, June 11 JOULWAN GEORGE A sold $264,448 worth of Emergent BioSolutions Inc. (NYSE:EBS) or 5,000 shares.

Emergent BioSolutions Inc. (NYSE:EBS) Ratings Coverage

Among 5 analysts covering Emergent BioSolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Emergent BioSolutions had 5 analyst reports since January 24, 2018 according to SRatingsIntel. The stock of Emergent BioSolutions Inc. (NYSE:EBS) has “Buy” rating given on Monday, June 11 by Cantor Fitzgerald. The rating was downgraded by Wells Fargo to “Hold” on Tuesday, April 24. Singular Research maintained the shares of EBS in report on Tuesday, February 27 with “Buy” rating. Below is a list of Emergent BioSolutions Inc. (NYSE:EBS) latest ratings and price target changes.

13/06/2018 Broker: Argus Research Rating: Buy New Target: $62 Initiates Coverage On
11/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $62.0000 Initiate
24/04/2018 Broker: Wells Fargo Rating: Hold New Target: $56.0000 Downgrade
27/02/2018 Broker: Singular Research Old Rating: Buy New Rating: Buy Old Target: $45 New Target: $60 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $55 Initiates Coverage On

The stock increased 0.27% or $0.15 during the last trading session, reaching $55.68. About 209,388 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has risen 65.53% since June 14, 2017 and is uptrending. It has outperformed by 52.96% the S&P500.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.77 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 32.64 P/E ratio. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

More notable recent Emergent BioSolutions Inc. (NYSE:EBS) news were published by: Globenewswire.com which released: “Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility” on June 07, 2018, also Streetinsider.com with their article: “Cantor Fitzgerald Starts Emergent BioSolutions (EBS) at Overweight” published on June 11, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on June 12, 2018. More interesting news about Emergent BioSolutions Inc. (NYSE:EBS) were released by: Benzinga.com and their article: “Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth” published on June 13, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For June 13, 2018” with publication date: June 13, 2018.

Emergent BioSolutions Inc. (NYSE:EBS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: